Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA's Biosimilar Suffix 'Error': Molehill Withdrawn But Mountain Coming?

Executive Summary

While FDA may envision suffix selection to be simple, sponsors and branding firms see a much more involved process.


Related Content

Biological Product Suffix Submissions Limited To 10 Candidates By US FDA
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes
Biosimilar Suffix Naming Idea Trips On Dispensing Problem


Related Companies